Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M295,446Revenue $M71,312Net Margin (%)23.3Z-Score5.7
Enterprise Value $M277,708EPS $4.8Operating Margin %28.1F-Score7
P/E(ttm))17.5Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yY
Price/Book3.910-y EBITDA Growth Rate %3.5Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-0.9Current Ratio2.6Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %23.6ROA % (ttm)13.1Higher Current Ratio y-yY
Dividend Yield %2.6Insider Buy (3m)0ROE % (ttm)23.1Less Shares Outstanding y-yY
Payout Ratio %45.0Shares Outstanding M2,799ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ Joel Greenblatt 2014-09-3014,31900.02New Buy
JNJ Ray Dalio 2014-09-3084,19300.07+27.77%
JNJ Dodge & Cox 2014-09-3047,09500+21.93%
JNJ John Rogers 2014-09-30536,6160.020.74+2.66%
JNJ Richard Pzena 2014-09-301,184,4160.040.69+2.49%
JNJ Jean-Marie Eveillard 2014-09-301,651,6220.060.44+1.73%
JNJ Richard Snow 2014-09-303,27000.01+0.77%
JNJ Ruane Cunniff 2014-09-3076,25900.04+0.32%
JNJ Richard Perry 2014-09-30342,2770.011.3
JNJ Warren Buffett 2014-09-30327,1000.010.03
JNJ John Hussman 2014-09-301,32500.01
JNJ Brian Rogers 2014-09-304,633,0000.171.8
JNJ Tom Gayner 2014-09-30574,2000.021.7
JNJ Michael Price 2014-09-3035,00000.47
JNJ Ken Fisher 2014-09-3010,446,1560.372.4-0.02%
JNJ PRIMECAP Management 2014-09-3012,217,8130.441.4-0.2%
JNJ Tweedy Browne 2014-09-304,163,9340.1510.2-0.77%
JNJ Mario Gabelli 2014-09-30366,3660.010.21-1.83%
JNJ Prem Watsa 2014-09-3082,85000.6-2.18%
JNJ Yacktman Fund 2014-09-303,900,0000.143.6-3.7%
JNJ Donald Yacktman 2014-09-308,651,2580.313.8-4.36%
JNJ Robert Olstein 2014-09-3083,00001.2-4.6%
JNJ Yacktman Focused Fund 2014-09-303,100,0000.113.5-6.06%
JNJ James Barrow 2014-09-3015,350,6500.552.2-10.05%
JNJ HOTCHKIS & WILEY 2014-09-302,86200-99.8%
JNJ George Soros 2014-09-30000Sold Out
JNJ Mark Hillman 2013-12-3130,74604.2-0.27%
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JOHNSON & JOHNSON10% Owner 2014-12-12Sell5,000$7.511268.31view
JOHNSON & JOHNSON10% Owner 2014-12-10Sell8,300$7.721231.09view
JOHNSON & JOHNSON10% Owner 2014-12-05Sell15,900$7.761224.23view
JOHNSON & JOHNSON10% Owner 2014-12-01Sell1,200$7.541262.86view
JOHNSON & JOHNSON10% Owner 2014-11-26Sell2,000$7.751225.94view
JOHNSON & JOHNSON10% Owner 2014-11-24Sell9,500$8.141162.41view
JOHNSON & JOHNSON10% Owner 2014-11-12Buy40,000$18470.89view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-5.33view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-4.35view
CULLEN JAMESDirector 2014-09-10Sell2,446$104.12-1.31view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Boston Scientific Lost the First Place in Innovation Dec 11 2014 
    Dividends vs. Stock Buybacks Dec 09 2014 
    Dividend Aristocrats In Focus Part 52 of 54: Johnson & Johnson Dec 03 2014 
    test_app_3 Nov 28 2014 
    test_app_3 Nov 28 2014 
    test_app_2 Nov 28 2014 
    test_app Nov 28 2014 
    U.S. Stocks Attractive As Euro-Area Economy Slides Nov 26 2014 
    Consolidated Edison Has Increased Dividends for 40 Years Nov 25 2014 
    Buy & Hold – Boring and Outdated Way to Invest? Nov 24 2014 


    More From Other Websites
    Is This The Future Of Late-Stage Drug Development? Dec 15 2014
    Sucampo Appoints John H. Johnson to Board of Directors Dec 15 2014
    J&J Tuberculosis Drug Poised for Expanded Reach Dec 11 2014
    Johnson & Johnson Announces Collaboration between Janssen and USAID to Expand Access to... Dec 11 2014
    APAC Joint Replacement Market to Reach $6.4 Billion by 2020 Dec 10 2014
    Covidien Loses $176M Award in Patent Case Against JNJ Unit Dec 09 2014
    Stop Waiting for Johnson & Johnson To Break Up or Down Dec 09 2014
    Top Global Stocks: Jazz, Actavis In IBD's World List Dec 08 2014
    Ebola, Ethics, And The New Normal Of Scary Germs Dec 04 2014
    Johnson & Johnson Dec 03 2014
    Alzheimer's drug shows promise Dec 03 2014
    Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU Dec 02 2014
    Biogen Alzheimer's Drug Succeeding In Early Tests Dec 02 2014
    Australian Diabetes Management Market and Diabetes Diagnostic Devices Market Spurted by $46 Million... Dec 01 2014
    Johnson & Johnson's Rezolsta Approved in the EU for HIV-1 Nov 27 2014
    Spanx for Your Face Nov 26 2014
    Health Care ETFs Healthy on a Global Basis, Too Nov 26 2014
    Apple eyes holiday sales Nov 26 2014
    Apple breaks $700 billion Nov 25 2014
    It was another slow, low volume, lackluster trading session Nov 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK